Both subgroups experienced reduced AF recurrence compared with those receiving drug therapy (<3 NMRRFs: AHR, 0.46 [95% CI, 0.40-0.52] and ≥3 NMRRFs: AHR, 0.58 [95% CI, 0.49-0.69]; P = .03 for interaction) (Figure 3). The gene discussed is AHR; the disease is atrial fibrillation.